530081-14-2

Basic information

• Product Name: 1-(4-Bromophenyl)imidazolidin-2-one
• Synonyms: 1-(4-Bromophenyl)imidazolidin-2-one;1-(4-Bromophenyl)tetrahydro-2H-imidazol-2-one, 1-Bromo-4-(2-oxoimidazolidin-1-yl)benzene
• CAS NO: 530081-14-2
• Molecular Formula: C₉H₉BrN₂O
• Molecular Weight: 241.08456
• Mol File: 530081-14-2.mol
• Article Data: 4

Chemical Properties

• Melting Point: 189～191℃
• Appearance: /
• Density: 1.579±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.79±0.20(Predicted)
• CAS DataBase Reference: 1-(4-Bromophenyl)imidazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Bromophenyl)imidazolidin-2-one(530081-14-2)
• EPA Substance Registry System: 1-(4-Bromophenyl)imidazolidin-2-one(530081-14-2)

Safety Data

• Hazardous Substances Data: 530081-14-2(Hazardous Substances Data)

Usage

Uses

1-(4-bromophenyl)tetrahydro-2H-imidazol-2-one is a useful research chemical.

Upstream product

• 106-40-1 4-bromo-aniline 
• 15145-38-7 1-(4-bromophenyl)-3-(2-chloroethyl)urea 
• 120-93-4 imidazolidone 
• 589-87-7 1,4-bromoiodobenzene 

Relevant articles and documents

Cathepsin K inhibitor and application thereof

The invention relates to a cathepsin K inhibitor and an application thereof, and specifically, relates to a compound and a drug composition thereof used for treating or preventing cathepsin dependence diseases, and the compound and the composition containing the compound can be used as a bone resorption inhibitor to treat relevant diseases. The cathepsin includes but is not limited to cathepsin K.

CYCLIC UREAS AS INHIBITORS OF ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.